1. Home
  2. WD vs CGEM Comparison

WD vs CGEM Comparison

Compare WD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Walker & Dunlop Inc

WD

Walker & Dunlop Inc

N/A

Current Price

$34.86

Market Cap

1.5B

Sector

Finance

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$14.71

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WD
CGEM
Founded
1937
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
WD
CGEM
Price
$34.86
$14.71
Analyst Decision
Buy
Strong Buy
Analyst Count
4
12
Target Price
★ $57.00
$33.45
AVG Volume (30 Days)
395.8K
★ 1.0M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 7.75%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.55
N/A
Revenue
★ $1,234,306,000.00
N/A
Revenue This Year
$12.87
N/A
Revenue Next Year
$12.04
$195.22
P/E Ratio
$65.67
★ N/A
Revenue Growth
★ 8.99
N/A
52 Week Low
$36.10
$5.68
52 Week High
$90.00
$23.19

Technical Indicators

Market Signals
Indicator
WD
CGEM
Relative Strength Index (RSI) 27.33 28.33
Support Level N/A $11.87
Resistance Level $52.37 $16.31
Average True Range (ATR) 1.25 1.26
MACD -0.22 -0.66
Stochastic Oscillator 0.00 12.11

Price Performance

Historical Comparison
WD
CGEM

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: